Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I

Immune tolerance induction for laronidase treatment in mucopolysaccharidosis I

Enzyme replacement therapy (ERT) can produce anti-drug antibody (ADA) responses that reduce efficacy or lead to hypersensitivity reactions. Six patients with severe mucopolysaccharidosis type I (MPS I/Hurler syndrome) who did not receive hematopoietic stem cell transplantation underwent an immunosup...

Full description

Bibliographic Details
Main Authors:	Roberto Giugliani, Taiane Alves Vieira, Clarissa Gutierrez Carvalho, Maria-Veronica Muñoz-Rojas, Alla N. Semyachkina, Victoria Y. Voinova, Susan Richards, Gerald F. Cox, Yong Xue
Format:	Article
Language:	English
Published:	Elsevier 2017-03-01
Series:	Molecular Genetics and Metabolism Reports
Subjects:	Mucopolysaccharidosis type I Enzyme replacement therapy Immune tolerance Laronidase Hurler syndrome Anti-drug antibodies
Online Access:	http://www.sciencedirect.com/science/article/pii/S2214426916301276

Similar Items

The impact of laronidase treatment in otolaryngological manifestations of patients with mucopolysaccharidosis
by: Ana Paula Fiuza Funicello Dualibi, et al.

Efficacy of a Combination Therapy with Laronidase and Genistein in Treating Mucopolysaccharidosis Type I in a Mouse Model
by: Marcelina Malinowska, et al.
Published: (2024-02-01)

Case Report: Mucopolysaccharidosis Type I Treatment With α-L-Iduronidase Replacement Therapy
by: Ying Li, et al.
Published: (2022-04-01)

Enzyme replacement therapy in Hurler syndrome after failure of hematopoietic transplant
by: Leonor Arranz, et al.
Published: (2015-06-01)

Enzyme replacement therapy for Mucopolysaccharidosis Type I among patients followed within the MPS Brazil Network
by: Alícia Dorneles Dornelles, et al.
Published: (2014-01-01)

Mucopolysaccharidosis Type I
by: Francyne Kubaski, et al.
Published: (2020-03-01)

Biomarkers for prediction of skeletal disease progression in mucopolysaccharidosis type I
by: Troy C. Lund, et al.
Published: (2021-03-01)

Intravenous Enzyme Replacement Therapy in Mucopolysaccharidoses: Clinical Effectiveness and Limitations
by: Rossella Parini, et al.
Published: (2020-04-01)

Elements of lentiviral vector design toward gene therapy for treating mucopolysaccharidosis I
by: Li Ou, et al.
Published: (2016-09-01)

Mucopolysaccharidosis: A broad review
by: Ritu Nagpal, et al.
Published: (2022-01-01)

Mucopolysaccharidosis Type I in the Russian Federation and Other Republics of the Former Soviet Union: Molecular Genetic Analysis and Epidemiology
by: E. Yu Voskoboeva, et al.
Published: (2022-01-01)

An online survey on burden of illness among families with post-stem cell transplant mucopolysaccharidosis type I children in the United States
by: Therese Conner, et al.
Published: (2019-02-01)

Open issues in Mucopolysaccharidosis type I-Hurler
by: Rossella Parini, et al.
Published: (2017-06-01)

Mucopolysaccharidosis Type 1 among Children—Neuroradiological Perspective Based on Single Centre Experience and Literature Review
by: Magdalena Machnikowska-Sokołowska, et al.
Published: (2023-01-01)

“Growth patterns in children with mucopolysaccharidosis type I-Hurler after hematopoietic stem cell transplantation: Comparison with untreated patients”
by: Alessandro Cattoni, et al.
Published: (2021-09-01)

Treatment of latent tuberculosis in a child with mucopolysaccharidosis type I receiving enzyme replacement therapy: A case report
by: Lauma Vasilevska, et al.
Published: (2022-08-01)

Mucopolysaccharidosis Type I: Current Treatments, Limitations, and Prospects for Improvement
by: Christiane S. Hampe, et al.
Published: (2021-01-01)

Rare cases of mucopolysaccharidosis type I in children with Hurler and Hurler-Scheie syndromes
by: A. E. Babushkin, et al.
Published: (2018-10-01)

Evaluation of Multiple Methods for Quantification of Glycosaminoglycan Biomarkers in Newborn Dried Blood Spots from Patients with Severe and Attenuated Mucopolysaccharidosis-I
by: Zackary M. Herbst, et al.
Published: (2020-08-01)

Lower Exposure to Busulfan Allows for Stable Engraftment of Donor Hematopoietic Stem Cells in Children with Mucopolysaccharidosis Type I: A Case Report of Four Patients
by: Praveen Shukla, et al.
Published: (2020-08-01)

The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases
by: P. K. Tandon, et al.
Published: (2021-04-01)

Anesthetic management in children with Hurler′s syndrome undergoing emergency ventriculoperitoneal shunt surgery
by: Nidhi Gupta, et al.
Published: (2012-01-01)

Genotypic and bioinformatic evaluation of the alpha-l-iduronidase gene and protein in patients with mucopolysaccharidosis type I from Colombia, Ecuador and Peru
by: Tatiana Pineda, et al.
Published: (2014-01-01)

Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment
by: Roberto Giugliani, et al.
Published: (2010-01-01)

A case report of a patient with mucopolysaccharidosis type II
by: M.R. Rivera Vega, et al.
Published: (2017-04-01)

Combining angiotensin receptor blockade and enzyme replacement therapy for vascular disease in mucopolysaccharidosis type I
by: Sarah C. Hurt, et al.
Published: (2024-03-01)

Evaluation of Demographic and Clinical Characteristics of Patients with Mucopolysaccharidosis
by: Pelin Teke Kısa, et al.
Published: (2017-06-01)

Alder-Reilly Anomaly in Patients with Mucopolysaccharidosis VI
by: Taiane Alves Vieira, et al.
Published: (2008-09-01)

Transcranial pulsed ultrasound facilitates brain uptake of laronidase in enzyme replacement therapy for Mucopolysaccharidosis type I disease
by: Yu-Hone Hsu, et al.
Published: (2017-06-01)

<i>Drosophila</i> D-idua Reduction Mimics Mucopolysaccharidosis Type I Disease-Related Phenotypes
by: Concetta De Filippis, et al.
Published: (2021-12-01)

Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data
by: Roberto Giugliani, et al.
Published: (2021-10-01)

Clinical manifestation of Hurler syndrome in a 7 year old child
by: S Sharma, et al.
Published: (2012-01-01)

A deletion of IDUA exon 10 in a family of Golden Retriever dogs with an attenuated form of mucopolysaccharidosis type I
by: Kiterie M. E. Faller, et al.
Published: (2020-09-01)

Visual Dysfunction of Type I and VI Mucopolysaccharidosis Patients Evaluated with Visual Evoked Cortical Potential
by: Bruno Duarte Gomes, et al.
Published: (2012-03-01)

Cardiac features and effects of enzyme replacement therapy in Taiwanese patients with Mucopolysaccharidosis IVA
by: Hsiang-Yu Lin, et al.
Published: (2018-08-01)

Novel approach to idursulfase and laronidase desensitization in type 2 and type 1 S mucopolysaccharidosis (MPS)
by: Federico Spataro, et al.
Published: (2022-11-01)

The Effects of Enzyme Replacement Therapy in Patients with Mucopolysaccharidosis Type 1: A Case Series Study
by: Peyman Eshraghi, et al.
Published: (2022-04-01)

The importance of the otorhinolaryngologic evaluation in mucopolysaccharidosis patients
by: Bicalho, Cibele Gomes, et al.
Published: (2011-07-01)

Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy
by: Yasuhiko Ago, et al.
Published: (2024-01-01)

SURGICAL TREATMENT OF CERVICAL STENOSIS IN PATIENTS WITH MUCOPOLYSACCHARIDOSIS: SYSTEMATIC REVIEW
by: S. V. Kolesov, et al.
Published: (2018-07-01)